Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical...

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy (CART) has revolutionized hematologic cancer treatment but shows limited efficacy in solid tumors.
• Metastatic colorectal cancer (mCRC) remains a significant challenge with few effective therapeutic options for refractory cases.

Purpose of the Study:

• To evaluate the safety and efficacy of guanylate cyclase-C (GCC19) CAR T-cell therapy (CART) in patients with metastatic colorectal cancer (mCRC).

Main Methods:

• A single-arm, phase 1 clinical trial involving adults with relapsed and refractory mCRC expressing GCC.
• Patients received GCC19CART, a combination of autologous CAR T cells targeting either CD-19 or GCC.
• Safety, tolerability, objective response rate, progression-free survival, and overall survival were assessed.

Main Results:

• GCC19CART was safe and tolerable, with manageable side effects like cytokine release syndrome and diarrhea.
• An objective response rate of 40% was observed.
• Median overall survival was 22.8 months, and median progression-free survival was 6.0 months in the high-dose group.

Conclusions:

• GCC19CART shows promise as a safe and tolerable treatment for heavily pretreated mCRC patients.
• This therapy is the first CAR T-cell therapy to demonstrate objective clinical activity in refractory solid tumors.
• Findings may support the development of effective cellular therapies for mCRC and other solid cancers.